Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers

M. C. Robson, Linda Phillips, A. Thomason, B. W. Altrock, P. C. Pence, J. P. Heggers, A. F. Johnston, T. P. McHugh, M. S. Anthony, L. E. Robson, L. L. Odom, D. Yanagihara, G. F. Pierce

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

A randomized phase I/II double-blind, placebo-controlled study was designed to evaluate 1, 10, and 100 μg/ml (0.01, 0.1, and 1.0 μg/cm2) recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) applied topically to chronic pressure ulcers for 28 days. Twenty patients were enrolled and completed the trial. No toxicities were associated with rPDGF-BB treatment. Patients treated with 100 μg/ml of rPDGF-BB had a pronounced healing response compared with placebo-treated patients. By day 29, ulcers treated with 100 μg/ml of rPDGF-BB were smaller in remaining size compared with those of placebo-treated patients when the following specific parameters were measured: percentage of initial depth (14.1 ± 7.4 vs. 34.9 ± 6.7) and percentage of initial volume (6.4 ± 4.0 vs. 21.8 ± 5.6). Histological analyses of biopsies revealed active wound healing processes in all groups with no disruption in the normal healing sequence in rPDGF-BB- treated wounds. The results of this small, descriptive study suggest rPDGF-BB is a potent vulnerary agent for accelerating soft-tissue repair, warranting further study.

Original languageEnglish (US)
Pages (from-to)193-201
Number of pages9
JournalAnnals of Plastic Surgery
Volume29
Issue number3
StatePublished - 1992

Fingerprint

Pressure Ulcer
Placebos
Therapeutics
platelet-derived growth factor BB
Wound Healing
Ulcer
Biopsy
Wounds and Injuries

ASJC Scopus subject areas

  • Surgery

Cite this

Robson, M. C., Phillips, L., Thomason, A., Altrock, B. W., Pence, P. C., Heggers, J. P., ... Pierce, G. F. (1992). Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers. Annals of Plastic Surgery, 29(3), 193-201.

Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers. / Robson, M. C.; Phillips, Linda; Thomason, A.; Altrock, B. W.; Pence, P. C.; Heggers, J. P.; Johnston, A. F.; McHugh, T. P.; Anthony, M. S.; Robson, L. E.; Odom, L. L.; Yanagihara, D.; Pierce, G. F.

In: Annals of Plastic Surgery, Vol. 29, No. 3, 1992, p. 193-201.

Research output: Contribution to journalArticle

Robson, MC, Phillips, L, Thomason, A, Altrock, BW, Pence, PC, Heggers, JP, Johnston, AF, McHugh, TP, Anthony, MS, Robson, LE, Odom, LL, Yanagihara, D & Pierce, GF 1992, 'Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers', Annals of Plastic Surgery, vol. 29, no. 3, pp. 193-201.
Robson, M. C. ; Phillips, Linda ; Thomason, A. ; Altrock, B. W. ; Pence, P. C. ; Heggers, J. P. ; Johnston, A. F. ; McHugh, T. P. ; Anthony, M. S. ; Robson, L. E. ; Odom, L. L. ; Yanagihara, D. ; Pierce, G. F. / Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers. In: Annals of Plastic Surgery. 1992 ; Vol. 29, No. 3. pp. 193-201.
@article{65efd1f5c9fe4bb1bab74f492dffb93d,
title = "Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers",
abstract = "A randomized phase I/II double-blind, placebo-controlled study was designed to evaluate 1, 10, and 100 μg/ml (0.01, 0.1, and 1.0 μg/cm2) recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) applied topically to chronic pressure ulcers for 28 days. Twenty patients were enrolled and completed the trial. No toxicities were associated with rPDGF-BB treatment. Patients treated with 100 μg/ml of rPDGF-BB had a pronounced healing response compared with placebo-treated patients. By day 29, ulcers treated with 100 μg/ml of rPDGF-BB were smaller in remaining size compared with those of placebo-treated patients when the following specific parameters were measured: percentage of initial depth (14.1 ± 7.4 vs. 34.9 ± 6.7) and percentage of initial volume (6.4 ± 4.0 vs. 21.8 ± 5.6). Histological analyses of biopsies revealed active wound healing processes in all groups with no disruption in the normal healing sequence in rPDGF-BB- treated wounds. The results of this small, descriptive study suggest rPDGF-BB is a potent vulnerary agent for accelerating soft-tissue repair, warranting further study.",
author = "Robson, {M. C.} and Linda Phillips and A. Thomason and Altrock, {B. W.} and Pence, {P. C.} and Heggers, {J. P.} and Johnston, {A. F.} and McHugh, {T. P.} and Anthony, {M. S.} and Robson, {L. E.} and Odom, {L. L.} and D. Yanagihara and Pierce, {G. F.}",
year = "1992",
language = "English (US)",
volume = "29",
pages = "193--201",
journal = "Annals of Plastic Surgery",
issn = "0148-7043",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers

AU - Robson, M. C.

AU - Phillips, Linda

AU - Thomason, A.

AU - Altrock, B. W.

AU - Pence, P. C.

AU - Heggers, J. P.

AU - Johnston, A. F.

AU - McHugh, T. P.

AU - Anthony, M. S.

AU - Robson, L. E.

AU - Odom, L. L.

AU - Yanagihara, D.

AU - Pierce, G. F.

PY - 1992

Y1 - 1992

N2 - A randomized phase I/II double-blind, placebo-controlled study was designed to evaluate 1, 10, and 100 μg/ml (0.01, 0.1, and 1.0 μg/cm2) recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) applied topically to chronic pressure ulcers for 28 days. Twenty patients were enrolled and completed the trial. No toxicities were associated with rPDGF-BB treatment. Patients treated with 100 μg/ml of rPDGF-BB had a pronounced healing response compared with placebo-treated patients. By day 29, ulcers treated with 100 μg/ml of rPDGF-BB were smaller in remaining size compared with those of placebo-treated patients when the following specific parameters were measured: percentage of initial depth (14.1 ± 7.4 vs. 34.9 ± 6.7) and percentage of initial volume (6.4 ± 4.0 vs. 21.8 ± 5.6). Histological analyses of biopsies revealed active wound healing processes in all groups with no disruption in the normal healing sequence in rPDGF-BB- treated wounds. The results of this small, descriptive study suggest rPDGF-BB is a potent vulnerary agent for accelerating soft-tissue repair, warranting further study.

AB - A randomized phase I/II double-blind, placebo-controlled study was designed to evaluate 1, 10, and 100 μg/ml (0.01, 0.1, and 1.0 μg/cm2) recombinant human BB homodimeric platelet-derived growth factor (rPDGF-BB) applied topically to chronic pressure ulcers for 28 days. Twenty patients were enrolled and completed the trial. No toxicities were associated with rPDGF-BB treatment. Patients treated with 100 μg/ml of rPDGF-BB had a pronounced healing response compared with placebo-treated patients. By day 29, ulcers treated with 100 μg/ml of rPDGF-BB were smaller in remaining size compared with those of placebo-treated patients when the following specific parameters were measured: percentage of initial depth (14.1 ± 7.4 vs. 34.9 ± 6.7) and percentage of initial volume (6.4 ± 4.0 vs. 21.8 ± 5.6). Histological analyses of biopsies revealed active wound healing processes in all groups with no disruption in the normal healing sequence in rPDGF-BB- treated wounds. The results of this small, descriptive study suggest rPDGF-BB is a potent vulnerary agent for accelerating soft-tissue repair, warranting further study.

UR - http://www.scopus.com/inward/record.url?scp=0026737331&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026737331&partnerID=8YFLogxK

M3 - Article

VL - 29

SP - 193

EP - 201

JO - Annals of Plastic Surgery

JF - Annals of Plastic Surgery

SN - 0148-7043

IS - 3

ER -